JP2011256204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011256204A5 JP2011256204A5 JP2011199945A JP2011199945A JP2011256204A5 JP 2011256204 A5 JP2011256204 A5 JP 2011256204A5 JP 2011199945 A JP2011199945 A JP 2011199945A JP 2011199945 A JP2011199945 A JP 2011199945A JP 2011256204 A5 JP2011256204 A5 JP 2011256204A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- microspheres
- composition according
- microns
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004005 microsphere Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 27
- 108091034117 Oligonucleotide Proteins 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 12
- 101150013553 CD40 gene Proteins 0.000 claims description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 10
- 230000001363 autoimmune Effects 0.000 claims description 10
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- -1 respectively Proteins 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000005784 autoimmunity Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 108010055896 polyornithine Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 241001427367 Gardena Species 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57027304P | 2004-05-12 | 2004-05-12 | |
| US60/570,273 | 2004-05-12 | ||
| US62548304P | 2004-11-05 | 2004-11-05 | |
| US60/625,483 | 2004-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513370A Division JP2007537288A (ja) | 2004-05-12 | 2005-05-12 | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011256204A JP2011256204A (ja) | 2011-12-22 |
| JP2011256204A5 true JP2011256204A5 (enExample) | 2013-10-03 |
| JP5457414B2 JP5457414B2 (ja) | 2014-04-02 |
Family
ID=35134160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513370A Pending JP2007537288A (ja) | 2004-05-12 | 2005-05-12 | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 |
| JP2011199945A Expired - Fee Related JP5457414B2 (ja) | 2004-05-12 | 2011-09-13 | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513370A Pending JP2007537288A (ja) | 2004-05-12 | 2005-05-12 | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7884085B2 (enExample) |
| EP (1) | EP1758558B1 (enExample) |
| JP (2) | JP2007537288A (enExample) |
| CN (1) | CN103432079A (enExample) |
| AU (1) | AU2005244851B2 (enExample) |
| CA (1) | CA2566199C (enExample) |
| DK (1) | DK1758558T3 (enExample) |
| ES (1) | ES2442115T3 (enExample) |
| MX (1) | MXPA06012989A (enExample) |
| PT (1) | PT1758558E (enExample) |
| WO (1) | WO2005112885A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| EP2072040B1 (en) * | 2004-05-12 | 2013-05-01 | Baxter International Inc. | Therapeutic use of nucleic acid micropheres |
| US7884085B2 (en) * | 2004-05-12 | 2011-02-08 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| JP2008539259A (ja) * | 2005-04-27 | 2008-11-13 | バクスター・インターナショナル・インコーポレイテッド | 表面を修飾した微粒子およびその形成方法および使用 |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| JP2009534309A (ja) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | 治療剤の標的化送達のためのシステム |
| EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
| US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
| US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| AU2007281737B2 (en) * | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| AU2013213750B2 (en) * | 2006-08-04 | 2013-09-26 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| CA2663589A1 (en) * | 2006-10-06 | 2008-05-22 | Baxter International Inc. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
| EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
| EP2144600A4 (en) | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | POLY (AMINIC ACID) TARGET MOLECULES |
| EP2620157A3 (en) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| EP2982753B1 (en) | 2008-04-18 | 2018-06-06 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US8367427B2 (en) * | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8323615B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
| US20100047292A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing microparticles and compositions produced thereby |
| US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| CA2929310C (en) | 2013-11-18 | 2024-07-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | MICROSPHERE-BASED ADMINISTRATION AND EX VIVO MANIPULATION OF DENDRITE CELLS FOR AUTOIMMUNE THERAPIES |
| EP3494219A1 (en) * | 2016-08-03 | 2019-06-12 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US373337A (en) * | 1887-11-15 | Shaft-hanger | ||
| DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
| JPS523342B2 (enExample) | 1972-01-26 | 1977-01-27 | ||
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4584894A (en) | 1984-02-29 | 1986-04-29 | Borg-Warner Corporation | Transmission anti-clash and anti-rattle brake |
| US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| EP0190833B1 (en) | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US5102872A (en) | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
| GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
| EP0248531A3 (en) | 1986-05-02 | 1988-09-28 | Southern Research Institute | Encapsulated nucleic acids |
| ES2053549T3 (es) | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion. |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US4848542A (en) * | 1988-04-18 | 1989-07-18 | Richard Burnette | Package for retaining and mounting a mirror |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| USRE38385E1 (en) | 1989-02-16 | 2004-01-13 | Nektar Therapeutics | Storage of materials |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| ATE133087T1 (de) | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| JP3359919B2 (ja) | 1990-05-16 | 2002-12-24 | サザン・リサーチ・インスティテュート | 放出制御ドーパミンおよび神経線維成長を刺激するための用途 |
| JPH0436233A (ja) * | 1990-05-29 | 1992-02-06 | Biomaterial Universe Kk | 生理活性物質含有生体内分解吸収性の徐放性製剤 |
| GB9016885D0 (en) | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| AU1442592A (en) | 1991-02-20 | 1992-09-15 | Nova Pharmaceutical Corporation | Controlled release microparticulate delivery system for proteins |
| US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| US5525519A (en) | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| US5173454A (en) | 1992-01-09 | 1992-12-22 | Corning Incorporated | Nanocrystalline materials |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| DE4211169C1 (enExample) | 1992-03-31 | 1993-06-03 | Klaus Kretzschmar | |
| JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| EP0595030A3 (en) | 1992-10-01 | 1995-06-07 | Tanabe Seiyaku Co | Multi-core microspheres with delayed drug delivery and process for their manufacture. |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| WO1994018947A1 (en) * | 1993-02-16 | 1994-09-01 | Sharifa Karali | High purity protamine-dna complex and use of same |
| EP0809110B1 (en) | 1993-03-09 | 2004-01-28 | Baxter International Inc. | Macromolecular microparticles and methods of production |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| DE69432867T2 (de) | 1993-11-18 | 2004-04-22 | Sirtex Medical Ltd., Burswood | Zubereitung mit gesteuerter freisetzung |
| US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| JPH09505308A (ja) | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | 生物学的活性剤を含有する生分解性微粒子の製造 |
| US5858973A (en) | 1994-02-23 | 1999-01-12 | The General Hospital Corporation | Transcription factor and uses therefor |
| DE69531992T2 (de) | 1994-08-04 | 2004-07-22 | Elan Drug Delivery Ltd., Ruddington | Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US5542920A (en) | 1994-09-12 | 1996-08-06 | Delab | Needle-less parenteral introduction device |
| US6387399B1 (en) | 1994-12-02 | 2002-05-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulated bioactive agents and method of making |
| US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| SE505146C2 (sv) | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
| US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US5958769A (en) | 1996-01-18 | 1999-09-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
| GB9607035D0 (en) | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0920339A2 (en) | 1996-07-09 | 1999-06-09 | The Johns Hopkins University | Gene delivery system |
| US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
| US6077833A (en) | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US20020182258A1 (en) * | 1997-01-22 | 2002-12-05 | Zycos Inc., A Delaware Corporation | Microparticles for delivery of nucleic acid |
| US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
| WO1998046212A1 (en) | 1997-04-17 | 1998-10-22 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
| GEP20022707B (en) | 1997-07-18 | 2002-06-25 | Infimed Inc Us | Biodegrading Macromers for the Controlled Release of Biologically Active Substances |
| WO1999008984A1 (en) * | 1997-08-18 | 1999-02-25 | Exxon Chemical Patents Inc. | Process to alkylate an aromatic with a dilute stream comprising propylene and ethylene |
| US6042792A (en) | 1997-09-18 | 2000-03-28 | International Flavors & Fragrances Inc. | Apparatus for preparing a solid phase microparticulate composition |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| AU749625B2 (en) * | 1998-01-16 | 2002-06-27 | Johns Hopkins University, The | Oral delivery of nucleic acid vaccines by particulate complexes |
| US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
| US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| US6197584B1 (en) | 1998-05-01 | 2001-03-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 expression |
| AU5345999A (en) | 1998-08-14 | 2000-03-06 | Valentis, Inc. | Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods |
| US6270802B1 (en) | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| EP1143934B1 (en) * | 1999-01-13 | 2003-06-04 | Johns Hopkins University School of Medicine | Genetic immunization with co-delivery of nucleic acid and cytokines |
| GB9904627D0 (en) * | 1999-03-02 | 1999-04-21 | Danbiosyst Uk | Polymer compositions for polynucleotide delivery |
| US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| EP1173151B1 (en) | 1999-04-16 | 2003-07-09 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| CA2369747A1 (en) | 1999-04-30 | 2000-11-09 | The Trustees Of The University Of Pennsylvania | Mutant human cd80 and compositions for and methods of making and using the same |
| AU5211200A (en) | 1999-05-04 | 2000-11-17 | Genethor Gmbh | Method for diminishing specific immune reactions |
| ES2207123T3 (es) | 1999-06-14 | 2004-05-16 | Baxter International Inc. | Microesferas de liberacion sostenida. |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| FR2809309B1 (fr) | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
| AU6206701A (en) | 2000-05-26 | 2001-12-03 | Symphogen As | Recombinant or purified polyclonal antibodies for treating allergy |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| KR100392501B1 (ko) | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| US6471995B1 (en) | 2000-09-27 | 2002-10-29 | Alkermes Controlled Therapeutics, Inc. Ii | Apparatus and method for preparing microparticles using liquid-liquid extraction |
| JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| SE518007C2 (sv) | 2000-11-16 | 2002-08-13 | Bioglan Ab | Förfarande för framställning av mikropartiklar |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| EP1801123A3 (en) | 2000-12-28 | 2007-11-21 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US6896905B2 (en) | 2001-02-15 | 2005-05-24 | Rohm And Haas Company | Porous particles, their aqueous dispersions, and method of preparation |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
| EP1418890B1 (en) | 2001-08-16 | 2008-05-14 | Baxter International Inc. | Propellant-based microparticle formulations |
| US20080026068A1 (en) | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| GB0207440D0 (en) * | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
| US20030224055A1 (en) | 2002-05-28 | 2003-12-04 | Lewis David L. | Compositions and processes for inhibiting gene expression using polynucleotides |
| US6900998B2 (en) | 2002-05-31 | 2005-05-31 | Midwest Research Institute | Variable-speed wind power system with improved energy capture via multilevel conversion |
| WO2004001007A2 (en) | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20040014698A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
| CN1688275B (zh) | 2002-09-11 | 2012-05-30 | 田边三菱制药株式会社 | 微球的制备方法 |
| CA2508592A1 (en) | 2002-12-17 | 2004-07-15 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
| US20060002862A1 (en) | 2002-12-17 | 2006-01-05 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
| US20050053666A1 (en) | 2002-12-31 | 2005-03-10 | Stelios Tzannis | Antibody-containing particles and compositions |
| EP2335725B1 (en) | 2003-04-04 | 2016-10-12 | Genentech, Inc. | High concentration antibody and protein formulations |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| ES2216707B1 (es) | 2003-04-08 | 2005-12-16 | Josep Maria Aran Perramon | Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes. |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| US7066023B2 (en) | 2003-07-14 | 2006-06-27 | Environmental Security Corporation | Distributed sensor array for fluid contaminant monitoring |
| US20050147687A1 (en) | 2003-07-18 | 2005-07-07 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| CA2553104A1 (en) | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| EP1713502A1 (de) | 2004-02-12 | 2006-10-25 | MERCK PATENT GmbH | Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern |
| EP2072040B1 (en) * | 2004-05-12 | 2013-05-01 | Baxter International Inc. | Therapeutic use of nucleic acid micropheres |
| US7884085B2 (en) * | 2004-05-12 | 2011-02-08 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| JP2008505192A (ja) | 2004-06-14 | 2008-02-21 | メッドイミューン バクシーンズ，インコーポレイティド | 生物活性材料の高圧噴霧乾燥 |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| WO2006072527A1 (de) | 2005-01-05 | 2006-07-13 | Siemens Aktiengesellschaft | Head-up-display für ein kraftfahrzeug |
| JP4595112B2 (ja) | 2005-02-14 | 2010-12-08 | 独立行政法人産業技術総合研究所 | タンパク質の高効率分離または濃縮方法 |
| AU2005330672B2 (en) | 2005-04-18 | 2011-07-28 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
| RU2303833C2 (ru) | 2005-07-26 | 2007-07-27 | Самсунг Электро-Меканикс Ко., Лтд. | Осветительное устройство |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| AU2007281737B2 (en) * | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US8002046B2 (en) * | 2008-10-10 | 2011-08-23 | Neeb Daniel A | Apparatus for reducing the incidence of tampering with automatic fire sprinkler assemblies |
-
2005
- 2005-05-12 US US11/127,360 patent/US7884085B2/en not_active Expired - Lifetime
- 2005-05-12 AU AU2005244851A patent/AU2005244851B2/en not_active Ceased
- 2005-05-12 CN CN2012105929369A patent/CN103432079A/zh active Pending
- 2005-05-12 WO PCT/US2005/016689 patent/WO2005112885A2/en not_active Ceased
- 2005-05-12 MX MXPA06012989A patent/MXPA06012989A/es active IP Right Grant
- 2005-05-12 EP EP05749674.7A patent/EP1758558B1/en not_active Expired - Lifetime
- 2005-05-12 PT PT57496747T patent/PT1758558E/pt unknown
- 2005-05-12 JP JP2007513370A patent/JP2007537288A/ja active Pending
- 2005-05-12 DK DK05749674.7T patent/DK1758558T3/da active
- 2005-05-12 CA CA2566199A patent/CA2566199C/en not_active Expired - Lifetime
- 2005-05-12 ES ES05749674.7T patent/ES2442115T3/es not_active Expired - Lifetime
-
2010
- 2010-06-24 US US12/822,774 patent/US9115357B2/en not_active Expired - Fee Related
-
2011
- 2011-09-13 JP JP2011199945A patent/JP5457414B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011256204A5 (enExample) | ||
| JP5457414B2 (ja) | オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用 | |
| EP2072040B1 (en) | Therapeutic use of nucleic acid micropheres | |
| JP2016528897A (ja) | Ｒｎａを調節するための組成物および方法 | |
| EP2759595B1 (en) | Composition comprising an encapsulated antagomir | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| JP2007537288A5 (enExample) | ||
| AU2022203361A1 (en) | Compositions and methods for modulating RNA | |
| JP5620946B2 (ja) | 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物 | |
| US20240279687A1 (en) | Peptide nucleic acids for spatiotemporal control of crispr-cas binding | |
| WO2024124315A1 (en) | Antisense oligonucleotide analogs of mir-29 and uses thereof | |
| WO2020257779A1 (en) | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof | |
| CN1980640A (zh) | 核酸微球体，其制备和递送 | |
| EP4119665A1 (en) | Sirna based on rna sequence of sars-cov-2 and use thereof |